Adult adherent stromal cells in the management of graft-versus-host disease

Expert Opinion on Biological Therapy

Volumn 14, Issue 2, 2014, Pages 231-246

  Newell, Laura F ^a   Deans, Robert J ^b   Maziarz, Richard T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ATHERSYS INC   (United States)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; Mesenchymal stromal cells

Indexed keywords

CANADA; CELL THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; MESENCHYMAL STROMA CELL; NEW ZEALAND; NONHUMAN; PROCESS OPTIMIZATION; REVIEW;

ADULT; ANIMALS; BIOLOGICAL PRODUCTS; CANADA; CHILD; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; MESENCHYMAL STEM CELL TRANSPLANTATION; NEW ZEALAND; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROMAL CELLS; TREATMENT OUTCOME;

EID: 84891904273     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.866648     Document Type: Review

References (100)

1. Friedenstein AJ, Chailakhyan RK, Latsinik NV, et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974;17(4):331-40
2. Dexter TM, Moore MA. In vitro duplication and "cure" of haemopoietic defects in genetically anaemic mice. Nature 1977;269(5627):412-14
3. Huang E, Nocka K, Beier DR, et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990;63(1):225-33
4. Nocka K, Tan JC, Chiu E, et al. Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J 1990;9(6):1805-13
5. Bubnic SJ, Wang XH, Clark BR, Keating A. W/Wv marrow stromal cells engraft and enhance early erythropoietic progenitors in unconditioned Sl/Sld murine recipients. Bone Marrow Transplant 2002;30(12):867-72
6. Majumdar MK, Thiede MA, Mosca JD, et al. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol 1998;176(1):57-66
7. Verfaillie CM. Soluble factor(s) produced by human bone marrow stroma increase cytokine-induced proliferation and maturation of primitive hematopoietic progenitors while preventing their terminal differentiation. Blood 1993;82(7):2045-53
8. Nolta JA, Hanley MB, Kohn DB. Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: analysis of gene transduction of long-lived progenitors. Blood 1994;83(10):3041-51
9. Fried W, Kedo A, Barone J. Effects of cyclophosphamide and of busulfan on spleen colony-forming units and on hematopoietic stroma. Cancer Res 1977;37(4):1205-9
10. McManus PM, Weiss L. Busulfan-induced chronic bone marrow failure: changes in cortical bone, marrow stromal cells, and adherent cell colonies. Blood 1984;64(5):1036-41
11. Nikkels PG, de Jong JP, Ploemacher RE. Long-term effects of cytostatic agents on the hemopoietic stroma: a comparison of four different assays. Leuk Res 1987;11(9):817-25
12. Migliaccio AR, Migliaccio G, Johnson G, et al. Comparative analysis of hematopoietic growth factors released by stromal cells from normal donors or transplanted patients. Blood 1990;75(1):305-12
13. Uhlman DL, Verfaillie C, Jones RB, Luikart SD. BCNU treatment of marrow stromal monolayers reversibly alters haematopoiesis. Br J Haematol 1991;78(3):304-9
14. Tavassoli M. The role of conditioning regimens in homing of transplanted hemopoietic cells. Bone Marrow Transplant 1992;10(1):15-17
15. O'Flaherty E, Sparrow R, Szer J. Bone marrow stromal function from patients after bone marrow transplantation. Bone Marrow Transplant 1995;15(2):207-12
16. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8(4):315-17
17. Campagnoli C, Roberts IA, Kumar S, et al. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001;98(8):2396-402
18. in 't Anker PS, Noort WA, Scherjon SA, et al. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 2003; 88(8): 845-52.
19. Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 2004;22(4):625-34
20. Le Blanc K, Tammik L, Sundberg B, et al. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003;57(1):11-20
21. Hoogduijn MJ, Crop MJ, Peeters AM, et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev 2007;16(4):597-604
22. Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003;101(9):3722-9
23. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005;105(5):2214-19
24. Jiang XX, Zhang Y, Liu B, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005;105(10):4120-6
25. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006;107(1):367-72
26. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2005;2:8
27. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009;113(26):6576-83
28. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105(4):1815-22
29. Lazarus HM, Haynesworth SE, Gerson SL, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995;16(4):557-64
30. Koc ON, Gerson SL, Cooper BW, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000;18(2):307-16
31. Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005;11(5):389-98
32. Frassoni F, Labopin M, Bacigalupo A, et al. Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hematopoietic stem cell transplants, reduce acute and chronic graft-versus-host disease: a matched pair analysis. Bone Marrow Transplant 2002;29(Suppl 2):abstract S2
33. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99(10):3838-43
34. Klyushnenkova E, Mosca JD, Zernetkina V, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005;12(1):47-57
35. Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363(9419):1439-41
36. Ringdén O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006;81(10):1390-7
37. Le Blanc K, Frassoni F, Ball L, et al. Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008;371(9624):1579-86
38. Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009;15(7):804-11
39. Prasad VK, Lucas KG, Kleiner GI, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011;17(4):534-41
40. Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GVHD Trials. Available from: http://investor.osiris.com/releasedetail. cfm?releaseid = 407404 [Last accessed 2 June 2013]
41. Martin PJ, Uberti JP, Soiffer RJ, et al. Prochymal improves response rates in patients with Steroid-Refractory Acute Graft Versus Host Disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 2010;16(2):S169-70
42. Szabolcs P, Visani G, Locatelli F, et al. Treatment of steroid-refractory acute GVHD with mesenchymal stem cells improves outcomes in pediatric patients; results of the pediatric subset in a phase iii randomized, placebo-controlled study. Biol Blood Marrow Transplant 2010;16(2):S298
43. World's first approved stem cell drug; osiris receives marketing clearance from health Canada for prochymal. Available from: http://www.osiris. com/pdf/2012-05-17%20Health%20Canada%20Release. pdf [Last accessed 2 June 2013]
44. Osiris wins race to market a stem cell product with Canadian go-ahead. Available from: http://www.genengnews. com/gen-news-highlights/osiris-wins-race- to-market-a-stem-cell-product-with-canadian-go-ahead/81246789/[Last accessed 30 May 2013]
45. Health Canada: report of the Expert Advisory Panel on Prochymal. Available from: http://www.hc-sc.gc.ca/dhp-mps/brgtherap/activit/sci-consult/ prochymal/report-rapport-eng.php [Last accessed 1 May 2013]
46. Wernicke CM, Grunewald TG, Juenger H, et al. Mesenchymal stromal cells for treatment of steroid-refractory GvHD: a review of the literature and two pediatric cases. Int Arch Med 2011;4(1):27
47. Pluristem therapeutics set to enter bone marrow disease market as it is preparing to apply for orphan drug status with the FDA for the treatment of aplastic bone marrow. Available from: http://www. checkorphan.org/grid/news/ treatment/pluristem-therapeutics-set-to-enter-bone-marrow-disease-market-as-it- is-preparing-to-apply-for-orphan-drug-status-with-the-fda-for-the-treatment-of- aplastic-bone-marrow [Last accessed 1 June 2013]
48. Or R, Grisaro S, Avni BR, et al. Abstract 4133: correction of post-transplant hematopoiesis by novel use of mesenchymal-like placental expanded cells (PLX) administered intra-muscular. Blood (ASH Annual Meeting Abstracts) 2012;120:abstract 4133
49. Colter DC, Class R, DiGirolamo CM, Prockop DJ. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci USA 2000;97(7):3213-18
50. Samuelsson H, Ringdén O, Lonnies H, Le Blanc K. Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy 2009;11(2):129-36
51. Bieback K, Hecker A, Kocaomer A, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009;27(9):2331-41
52. Horwitz EM, Gordon PL, Koo WK, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA 2002;99(13):8932-7
53. Ben Azouna N, Jenhani F, Regaya Z, et al. Phenotypical and functional characteristics of mesenchymal stem cells from bone marrow: comparison of culture using different media supplemented with human platelet lysate or fetal bovine serum. Stem Cell Res Ther 2012;3(1):6
54. Bieback K, Ha VA, Hecker A, et al. Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. Tissue Eng Part A 2010;16(11):3467-84
55. Kocaoemer A, Kern S, Klüter H, Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007;25(5):1270-8
56. Avanzini MA, Bernardo ME, Cometa AM, et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood-and bone marrow-derived progenitors. Haematologica 2009;94(12):1649-60
57. Polchert D, Sobinsky J, Douglas G, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008;38(6):1745-55
58. Brindley DA, Davie NL, Culme-Seymour EJ, et al. Peak serum: implications of serum supply for cell therapy manufacturing. Regen Med 2012;7(1):7-13
59. Burrows GG, van't Hof W, Newell L, et al. Dissection of the human multipotent adult progenitor cell (MAPC) secretome by proteomic analysis. Stem Cells Transl Med 2013;2(10):745-57
60. Burrows GG, Maziarz RT, Hunady K, et al. Human multipotent adult progenitor cells transcriptionally regulate fucosyltransferase VII. Cytotherapy 2013. [Epub ahead of print]
61. Maziarz RT, deVos T, Bachier C, et al. Prophylaxis of acute GVHD using multistem stromal cell therapy: preliminary results after administration of single or multiple doses in a phase 1 trial. Biol Blood Marrow Transplant 2012;18(2):S264-5
62. Reading JL, Yang JH, Sabbah S, et al. Clinical-grade multipotent adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and autoimmunity. J Immunol 2013;190(9):4542-52
63. Weng JY, Du X, Geng SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010;45(12):1732-40
64. Zhou H, Guo M, Bian C, et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010;16(3):403-12
65. Uhlin M, Sairafi D, Berglund S, et al. Mesenchymal stem cells inhibit thymic reconstitution after allogeneic cord blood transplantation. Stem Cells Dev 2012;21(9):1409-17
66. Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010;16(6):838-47
67. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005;23(9):1993-2003
68. Djouad F, Plence P, Bony C, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-44
69. Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008;22:593-9
70. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant 2006;12(2):126-37
71. Goldberg JD, Giralt S. Assessing response of therapy for acute and chronic graft-versus-host disease. Expert Rev Hematol 2013;6(1):103-7
72. Kaiser T, Kamal H, Rank A, et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 2004;104(2):340-9
73. Weissinger EM, Schiffer E, Hertenstein B, et al. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007;109(12):5511-19
74. Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin or pentostatin plus corticosteroids for acute graft vs. host disease: a randomized phase II trial from the BMT CTN. Blood 2009;114(3):511-17
75. Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012;119(16):3854-60
76. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood 2009;113(2):273-8
77. Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010;2(13):13ra12
78. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3 alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 2011;118(25):6702-8
79. MacMillan ML, DeFor TE, Weisdorf DJ. What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol 2012; 157(6): 732-41
80. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002;8(7):387-94
81. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97(4):855-64
82. Hahn T, McCarthy PL Jr, Zhang MJ, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008;26(35):5728-34
83. Flowers ME, Inamoto Y, Carpenter PA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117(11):3214-19
84. Arora M, Klein JP, Weisdorf DJ, et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011;117(24):6714-20
85. Petersdorf EW. Genetics of graft-versus-host disease: the major histocompatibility complex. Blood Rev 2013;27(1):1-12
86. Pasquini MC, Devine S, Mendizabal A, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol 2012;30(26):3194-201
87. Barrett AJ, Mavroudis D, Tisdale J, et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998;21(6):543-51
88. Lee CK, deMagalhaes-Silverman M, Hohl RJ, et al. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Bone Marrow Transplant 2003;31(2):121-8
89. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009;10(5):489-500
90. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14(6):641-50
91. Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011;117(3):1061-70
92. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011;117(14):3921-8
93. Lee SJ, Vogelsang G, Gilman A, et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant 2002;8(1):32-9
94. Weisdorf DJ, Hurd D, Carter S, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant 2003;9(8):512-18
95. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006;108(2):749-55
96. Pavletic SZ, Martin P, Lee SJ, et al. Response Criteria Working Group. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006;12(3):252-66
97. Martin PJ, Bachier CR, Klingemann HG, et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant 2009;15(7):777-84
98. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22(7):1281-5
99. Weng J, He C, Lai P, et al. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Mol Ther 2012;20(12):2347-54
100. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009;373(9674):1550-61